We aim to develop innovative cancer therapies that are more effective and have fewer side effects than conventional therapies. Our approach is based on the highly potent toxin amanitin, derived from the death cap mushroom, which we are adapting for use in oncology.

Using our proprietary ADC technology, we conjugate Amanitin to specific antibodies that transport the toxin directly to tumor cells, which absorb it triggering tumor cell death. In this way, we combine the precision of modern antibody therapies with the exceptional efficacy of Amanitin to address even hard-to-treat cancers. Due to its unique mechanism of action, Amanitin offers the potential to overcome resistance to therapy and eliminate dormant tumor cells. For patients who no longer respond to any other treatment, this would represent a significant advance in treatment.

Our commitment is to translate scientific findings into clinically effective therapies, thereby creating new treatment options for cancer patients.